Back to results
US 2021/0261677 A1Published application
Anti-pd-l1 antibody and use thereof
AssigneeOrigincell Therapeutics Co., Ltd.
InventorsBohua LI, Huajing WANG, Xiaowen HE
Life of this patent
Estimating the term…
Abstract
Provided are an antibody that binds to the PD-L1 protein or CD137 protein, an antigen-binding fragment or a variant thereof, as well as a bispecific antibody that can bind to both the PD-L1 protein and the CD137 protein. The bispecific antibody has a strong ability to specifically recognize the PD-L1 protein and the CD137 protein, and can enhance T-cell activity. Also provided is the use of the antibody or the antigen-binding fragment or the variant thereof and the bispecific antibody in the prevention and treatment of tumors.
Claims14
1-72. (canceled)
A bispecific antibody, comprising:
- a first targeting moiety that specifically binds to a PD-L1 protein, and
- a second targeting moiety that specifically binds to a CD137 protein,
- wherein said first targeting moiety comprises an antibody, an antigen binding fragment or a variant thereof, and
- said second targeting moiety comprises an antibody, an antigen binding fragment or a variant thereof,
- said antibody of the first targeting moiety comprises an antibody heavy chain or a fragment thereof comprising HCDR1-3, and said HCDR1-3 comprises the amino acid sequences as set forth in SEQ ID NO:
- 47, 48 and 51, respectively,
- said antibody of the first targeting moiety comprises an antibody light chain or a fragment thereof comprising LCDR1-3, and said LCDR1-3 comprise the amino acid sequences as set forth in SEQ ID NO:
- 55, 60 and 64, respectively,
- said antibody of the second targeting moiety comprises an antibody heavy chain or a fragment thereof comprising HCDR1-3, and said HCDR1-3 comprises the amino acid sequences as set forth in SEQ ID NO:
- 77-79, respectively, and
- said antibody of the second targeting moiety comprises an antibody light chain or a fragment thereof comprising LCDR1-3, and said LCDR1-3 comprise the amino acid sequences as set forth in SEQ ID NO:
- 80-82, respectively.
9 more elements
Dependencies are inferred from the claim text.